Author:
Leinwand Joshua C.,Zhao Binsheng,Guo Xiaotao,Krishnamoorthy Saravanan,Qi Jing,Graziano Joseph H.,Slavkovic Vesna N.,Bates Gleneara E.,Lewin Sharyn N.,Allendorf John D.,Chabot John A.,Schwartz Lawrence H.,Taub Robert N.
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1–11.
2. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4(5):277–83.
3. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97:845–51.
4. Casper ES, Kelsen DP, Alcock NW, Lewis JL. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep. 1983;67:235–8.
5. Pretorius RG, Hacker NF, Berek JS, et al. Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 1983;67:1085–92.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献